LOGIN  |  REGISTER
C4 Therapeutics
Compass Therapeutics

Certara to Participate in Upcoming Investor Conferences

May 03, 2022 | Last Trade: US$8.17 0.16 -1.92

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences:

  • Bank of America 2022 Healthcare Conference
    Date and Time: Tuesday, May 10 at 3:00 p.m. ET
  • Citi’s Biopharma Virtual Co-Panel Day
    Date and Time: Wednesday, May 18 at 10:00 a.m. ET
  • Jefferies Healthcare Conference
    Date and Time: Wednesday, June 8 – Friday, June 10
    Details to be posted to the Company’s IR website
  • William Blair 42nd Annual Growth Stock Conference
    Date and Time: Thursday, June 9 at 10:20 a.m. ET

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page